Our rationale for assessing the anti-cancer and anti-angiogenesis effects of D2R agonists as a potential therapy to inhibit human SCLC progression stems from (1) our prior finding that D2R agonists inhibit angiogenesis and reduce tumour progression in murine models of NSCLC [60], (2) the role of dopamine signalling in physiological neuronal function [79], and (3) the neuroendocrine origin of SCLC [80]. The gene discussed is DRD2; the disease is non-small cell lung carcinoma.